Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies

A Multiple-center Phase II Study to Evaluate the Clinical Outcome of Reduced Conditioning Regimen With Melphalan, Busulfan and Fludarabine for Patients >=55 Years With Myeloid Malignancies.

In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML >=55 years.

Conditioning regimen with double alkylating agents such as busulfan + melphalan or Busulfan + thiotepa have been shown to improve the transplantation outcome in terms of lower relapse rate in various myeloid malignancies. In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML >=55 years.

Inclusion Criteria:

• Age 55-65
• patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors or haplo-identical donors.
• patients with AML in remission, or MDS in any stage, or CMML in any stage
• inform consent provided

Exclusion Criteria:

• patients with abnormal liver (>3N), renal (1.5N) or cardiac function
• patients with active infection